A random assignment phase II study of modified docetaxel, cisplatin, and fluorouracil (mDCF) versus parent DCF with growth factor support in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma

Study Status

Open to Enrollment

Study Description

Chemotherapy given together is a standard way to treat gastric or gastroesophageal junction (GEJ) cancer. One standard treatment includes a combination of docetaxel, cisplatin, and fluorouracil. However, the original combination of these three drugs can cause many side effects.

The purpose of this study is to find out if these three drugs can be given at lower doses more often, with fewer side effects and still maintain the same benefit as the standard way of giving this three drug combination.
If your tumor overexpresses a protein called Her2, you are also eligible to receive trastuzumab with chemotherapy. Trastuzumab is a medicine that has been approved by the FDA for the treatment of Her2 positive breast cancer. Trastuzumab is now also a standard treatment in combination with chemotherapy for the treatment of Her2 positive stomach cancer. If your tumor is Her2 positive, you would receive the modified administration schedule of docetaxel, cisplatin, and fluorouracil with trastuzumab.

Disease Status and/or Stage

Metastatic or Unresectable Gastric or Gastroesophageal Junction (GEJ) Cancer

Key Eligibility

  • Men and women ≥ age 18
  • Metastatic or unresectable gastric or gastroesophageal junction (GEJ) cancer
  • No prior chemotherapy for metastaic or unresectable disease. May have received prior adjuvant therapy (chemotherapy and/or chemoradiation) if > 6 months since end of adjuvant therapy
  • Detailed eligibility discussed when you contact the study team

Principal Investigator

Allyson Ocean, MD


Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Erica Bersin
Tel: (646) 962-8232
[email protected]

Top of page